PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment
Articles > Article · 2022
Authors: Pınar GÜRSOY, Burcu ÇAKAR, DAMLA GÜNENÇ, Deniz NART, Akın ÇİNKOOĞLU, Nuran Katgi
TURKISH THORACIC JOURNAL, Journal Indexed in SCI Expanded, International, 2022, vol 23, pp 45-51
DOI: 10.5152/turkthoracj.2022.21151
Summary
OBJECTIVE: To show the effect of programmed cell death protein-1 ligand level survival times in patients with metastatic non-small cell lung cancer receiving chemotherapy, to determine the relationship between programmed cell death protein-1 ligand level, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio.